Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

NovaBridge Biosciences

NBP · Nasdaq · CIK 0001778016 · Healthcare · Biotechnology

INSIDER SIGNAL

44.2 / 100

1 buyers · 1 purchase transaction lines · $577.3K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyLow
ConvictionModerate
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+13.9 / 25
Role+15.5 / 20
Recency+0.5 / 10
Conviction+7.3 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Role uses the day's average · no purchase states a title on the role scale
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Xu Cong ClaireSVP, Clinical Development
○▼○▼○▼
Dennis Phillip AndrewChief Medical Officer
○▼○▼
Cao Sean WuxiongSee Remarks
▼○▼
Hagler Mark ArnoldSee Remarks
●
Lenz Robert A.Director
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Hagler Mark Arnold · $577.3K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-04-24–2026-04-24

Roles in the peak window: See Remarks. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

44.2 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 44.4
  2. 44.3
  3. 44.3
  4. 44.2
  5. 44.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
7Sales
8Other Form 4 lines
10SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING7 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-17.5%
3M
-25.0%
6M
-40.9%
12M
-72.5%

Volatility & liquidity

Volatility
101.7%
Beta
—
Avg daily value
USD 529,130

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-20.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
3,282,485
Previous report
3,746,443
Avg daily volume
931,895
Days to cover
3.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-04-24Hagler Mark ArnoldPurchase (P)Ordinary Shares230,000USD 2.51USD 577,300SEC filing ↗

Form 4 evidence

16 transaction lines in the latest 365-day window; 16 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-18Dennis Phillip AndrewSale (S)Ordinary Shares8,209USD 0.71USD 5,828SEC filing ↗
2026-09-17Dennis Phillip AndrewOption exercise / conversion (M)Ordinary Shares23,695USD —USD —SEC filing ↗
2026-09-09Cao Sean WuxiongSale (S)Ordinary Shares107,978USD 0.74USD 79,904SEC filing ↗
Show recent Form 4 evidence (15 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-18Dennis Phillip AndrewSale (S)Ordinary Shares8,209USD 0.71USD 5,828SEC filing ↗
2026-09-17Dennis Phillip AndrewOption exercise / conversion (M)Ordinary Shares23,695USD —USD —SEC filing ↗
2026-09-09Cao Sean WuxiongSale (S)Ordinary Shares107,978USD 0.74USD 79,904SEC filing ↗
2026-09-03Cao Sean WuxiongOption exercise / conversion (M)Ordinary Shares339,372USD —USD —SEC filing ↗
2026-08-31Xu Cong ClaireSale (S)Ordinary Shares3,282USD 0.79USD 2,593SEC filing ↗
2026-08-30Xu Cong ClaireOption exercise / conversion (M)Ordinary Shares9,382USD —USD —SEC filing ↗
2026-08-22Lenz Robert A.Option exercise / conversion (M)Ordinary Shares17,218USD —USD —SEC filing ↗
2026-07-06Xu Cong ClaireSale (S)Ordinary Shares4,485USD 0.89USD 3,992SEC filing ↗
2026-07-04Xu Cong ClaireOption exercise / conversion (M)Ordinary Shares12,432USD —USD —SEC filing ↗
2026-06-18Dennis Phillip AndrewSale (S)Ordinary Shares8,494USD 0.66USD 5,606SEC filing ↗
2026-06-17Dennis Phillip AndrewOption exercise / conversion (M)Ordinary Shares23,695USD —USD —SEC filing ↗
2026-06-01Xu Cong ClaireSale (S)Ordinary Shares3,494USD 3.94USD 13,766SEC filing ↗
2026-05-30Xu Cong ClaireOption exercise / conversion (M)Ordinary Shares9,382USD —USD —SEC filing ↗
2026-05-14Cao Sean WuxiongSale (S)Ordinary Shares21,399USD 1.99USD 42,584SEC filing ↗
2026-04-24Hagler Mark ArnoldPurchase (P)Ordinary Shares230,000USD 2.51USD 577,300SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNBP
CIK0001778016
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history16 transaction lines from 2026-04-24 to 2026-09-18
1 P purchase lines · 7 S sale lines · 8 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.